التداخل بين لورلاتينيب وفيراباميل

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided.

Strong CYP3A Inhibitors Avoid concomitant use of LORBRENA with a strong CYP3A inhibitor.

Concomitant use with a strong CYP3A inhibitor increased lorlatinib plasma concentrations [see Clinical Pharmacology (12.3) ] , which may increase the incidence and severity of adverse reactions of LORBRENA.

CYP3A4 inducers decrease verapamil levels ( 7.1 )

Inducers of CYP3A4 (e.g., rifampin) have caused a lowering of plasma levels of verapamil.